Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.

L Szenborn,I V Osipova,H Czajka,S M Kharit,T Jackowska,N François,M A Habib,D Borys

Vaccine（2017）

引用 6|浏览21

暂无评分

摘要

•Immunogenicity and safety of PHiD-CV was studied in 2–17-year-old at-risk children.•46 children with asplenia or splenic dysfunction received 1 or 2 doses of PHiD-CV.•PHiD-CV was immunogenic in at-risk children and no safety concerns were identified.

查看译文

关键词

Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV),Immunogenicity,Safety,Asplenia,Splenic dysfunction

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要